An Introduction to Psoriasis
Psoriasis is a common, chronic inflammatory skin disease that can also affect the joints. Management involves topical and systemic medication, and phototherapy. In the past decade, increased understanding of the pathophysiology of autoimmune diseases has resulted in the development of systemic biologic therapies for moderate-to-severe disease, including inhibitors of tumour necrosis factor (TNF) α, and interleukins (IL)-12, IL-23 and IL-17A. Topical medications, including corticosteroids, vitamin D analogues, calcineurin inhibitors and keratolytics, remain the mainstay of treatment of mild-to-moderate disease. Therapies in the pipeline include tapinarof, a topical aryl hydrocarbon receptor modulating agent, and BMS-986165, an oral tyrosine kinase 2 inhibitor.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. These are complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Leon Kircik, AAD VMX 2021: Roflumilast Foam in Scalp and Body Psoriasis
Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and body psoriasis. His abstract entitled ‘Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A […]
Kim Papp, AAD VMX 2021: Secukinumab PURE Study
We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis. The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over […]
Siew Eng Choon, AAD VMX 2021: Unmet Needs in Generalised Pustular Psoriasis
It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the current unmet needs in the treatment of generalised pustular psoriasis (GPP). Disclosures: Dr Siew Eng Choon has received honoraria for serving as a consultant, advisory board member, and/or speaker for AbbVie, Boehringer Ingelheim, Janssen, Leo, Eli Lilly, Leo, Novartis, […]
Siew Eng Choon, AAD VMX 2021: Spesolimab in Generalised Pustular Psoriasis
It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the first RCT trial conducted in generalised pustular psoriasis (GPP). Effisayil 1 (NCT03782792) is a Phase 2 trial investigating the anti-IL-36 receptor antibody, spesolimab. The abstract entitled ‘Design and rationale of Effisayil 1, a Phase II, multicenter, randomized, double-blind, placebo-controlled […]
Tiago Torres, EADV Spring Symposium 2021: Psoriasis Session Highlights
It was a pleasure to discuss with Prof. Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) his highlights from the psoriasis session he chaired at the EADV Spring Symposium, 6-7 May 2021. Questions Could you give us a brief overview of the presentations on the psoriasis session that you chaired at EADV? (0:18) How has […]
Tiago Torres, EADV Spring Symposium 2021: Comorbidities in Psoriasis
We were delighted to speak with our Expert Faculty member, Prof. Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal), about the need to look for comorbidities in psoriasis. His talk entitled ‘Is there a need to look for comorbidities in psoriasis?’ was presented at the EADV Spring Symposium, 6-7 May 2021. Questions What cardiometabolic comorbidities […]
Lynda Grine, EADV Spring Symposium 2021: Intermittent Fasting in Psoriasis
It was a pleasure to speak with Dr Lynda Grine (Ghent University Hospital, Ghent, Belgium) about her research into the effects of intermittent fasting on psoriasis. Her presentation entitled ‘Interim results of the MANGO trial: effects of modified intermittent fasting in psoriasis’ was presented at the EADV Spring Symposium, 6-7 May 2021. Questions Could you […]
Linda Stein Gold, EADV Spring 2021: Roflumilast DERMIS-1 and DERMIS-2 Trials
TouchIMMUNOLOGY got the opportunity to catch up with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, US) around the use of roflumilast in the treatment of chronic plaque psoriasis patients (Clinical Trial Identifier: NCT04211363 & NCT04211389). The abstract ‘Roflumilast cream, a once-daily, potent phosphodiesterase-4 inhibitor, in chronic plaque psoriasis patients: Efficacy and safety […]
Diamant Thaçi, EADV 2020: Long-term Efficacy of Tildrakizumab in Psoriasis
It was an honour to talk with Prof. Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754). Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!